Medical technology company Shoulder Innovations Inc (NYSE: SI) on Monday announced the full commercial launch of the InSet 70 Humeral Stem, expanding its I-Series humeral stem product line that began with the InSet 95 in 2024.

The InSet 70 is indicated for both anatomic and reverse shoulder arthroplasty, addressing conditions including osteoarthritis, avascular necrosis, rheumatoid and traumatic arthritis, as well as functional deformities. In reverse procedures, it is also indicated for irreparable cuff tears and revision of other devices when adequate bone stock remains.

This launch strengthens Shoulder Innovations' shoulder arthroplasty portfolio, which is part of a broader ecosystem designed to enhance surgical planning, implant performance and procedural efficiency. The company's platform integrates advanced implant systems with enabling technologies, instrument systems and surgeon collaboration to improve outcomes and operational efficiency across the shoulder surgical care market.